Cargando…
Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma
BACKGROUND: Current guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically stage...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794188/ https://www.ncbi.nlm.nih.gov/pubmed/32969129 http://dx.doi.org/10.1002/onco.13542 |
_version_ | 1783634154012803072 |
---|---|
author | Margalit, Ofer Shacham‐Shmueli, Einat Yang, Yu‐Xiao Lawerence, Yaacov R. Levy, Idan Reiss, Kim A. Golan, Talia Halpern, Naama Aderka, Dan Giantonio, Bruce Mamtani, Ronac Boursi, Ben |
author_facet | Margalit, Ofer Shacham‐Shmueli, Einat Yang, Yu‐Xiao Lawerence, Yaacov R. Levy, Idan Reiss, Kim A. Golan, Talia Halpern, Naama Aderka, Dan Giantonio, Bruce Mamtani, Ronac Boursi, Ben |
author_sort | Margalit, Ofer |
collection | PubMed |
description | BACKGROUND: Current guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically staged patients identifies more advanced locoregional disease requiring adjuvant treatment. Therefore, identifying these patients prior to surgical intervention is critical to ensure employment of the appropriate treatment paradigm. The aim of the current study was to define patient characteristics associated with clinical understaging in early gastric cancer. METHODS: Using the National Cancer Database (2004–2014) we identified 3,892 individuals with clinical T1N0 gastric adenocarcinoma who underwent upfront definitive surgery, had negative surgical margins, and did not receive preoperative chemotherapy or radiotherapy. Patient characteristics were compared between those with pathologic stage T1N0 disease and those who were upstaged upon surgery. RESULTS: Twenty‐seven percent of clinical T1N0 gastric adenocarcinomas had a change in stage because of pathologically defined ≥T2 disease or positive lymph nodes. Individuals who were upstaged had a higher tumor grade compared with those with pathologic stage T1N0 disease. Specifically, 41.9% (530/1,264) of individuals with a poorly differentiated tumor were upstaged, compared with only 10.7% (70/656) with a well‐differentiated tumor. Approximately 75% of cases involved upstaging because of T misclassification. The highest percentage of upstaging was shown for tumors located at the fundus and body of the stomach. CONCLUSION: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. IMPLICATIONS FOR PRACTICE: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. |
format | Online Article Text |
id | pubmed-7794188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77941882021-01-15 Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma Margalit, Ofer Shacham‐Shmueli, Einat Yang, Yu‐Xiao Lawerence, Yaacov R. Levy, Idan Reiss, Kim A. Golan, Talia Halpern, Naama Aderka, Dan Giantonio, Bruce Mamtani, Ronac Boursi, Ben Oncologist Gastrointestinal Cancer BACKGROUND: Current guidelines recommend neoadjuvant chemotherapy in patients with locoregional gastric adenocarcinoma. Patients diagnosed with early stage gastric adenocarcinoma are usually managed with upfront surgical intervention. However, pathologic staging in a subset of these clinically staged patients identifies more advanced locoregional disease requiring adjuvant treatment. Therefore, identifying these patients prior to surgical intervention is critical to ensure employment of the appropriate treatment paradigm. The aim of the current study was to define patient characteristics associated with clinical understaging in early gastric cancer. METHODS: Using the National Cancer Database (2004–2014) we identified 3,892 individuals with clinical T1N0 gastric adenocarcinoma who underwent upfront definitive surgery, had negative surgical margins, and did not receive preoperative chemotherapy or radiotherapy. Patient characteristics were compared between those with pathologic stage T1N0 disease and those who were upstaged upon surgery. RESULTS: Twenty‐seven percent of clinical T1N0 gastric adenocarcinomas had a change in stage because of pathologically defined ≥T2 disease or positive lymph nodes. Individuals who were upstaged had a higher tumor grade compared with those with pathologic stage T1N0 disease. Specifically, 41.9% (530/1,264) of individuals with a poorly differentiated tumor were upstaged, compared with only 10.7% (70/656) with a well‐differentiated tumor. Approximately 75% of cases involved upstaging because of T misclassification. The highest percentage of upstaging was shown for tumors located at the fundus and body of the stomach. CONCLUSION: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. IMPLICATIONS FOR PRACTICE: Upstaging of clinical T1N0 gastric adenocarcinoma is characterized by higher tumor grade and is mostly a result of a change in T stage. These findings mandate thorough workup in order to identify patients with clinically staged T1N0 disease requiring preoperative chemotherapy. John Wiley & Sons, Inc. 2020-10-20 2021-01 /pmc/articles/PMC7794188/ /pubmed/32969129 http://dx.doi.org/10.1002/onco.13542 Text en © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Gastrointestinal Cancer Margalit, Ofer Shacham‐Shmueli, Einat Yang, Yu‐Xiao Lawerence, Yaacov R. Levy, Idan Reiss, Kim A. Golan, Talia Halpern, Naama Aderka, Dan Giantonio, Bruce Mamtani, Ronac Boursi, Ben Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma |
title | Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma |
title_full | Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma |
title_fullStr | Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma |
title_full_unstemmed | Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma |
title_short | Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma |
title_sort | prognostic implications of tumor differentiation in clinical t1n0 gastric adenocarcinoma |
topic | Gastrointestinal Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794188/ https://www.ncbi.nlm.nih.gov/pubmed/32969129 http://dx.doi.org/10.1002/onco.13542 |
work_keys_str_mv | AT margalitofer prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT shachamshmuelieinat prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT yangyuxiao prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT lawerenceyaacovr prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT levyidan prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT reisskima prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT golantalia prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT halpernnaama prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT aderkadan prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT giantoniobruce prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT mamtanironac prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma AT boursiben prognosticimplicationsoftumordifferentiationinclinicalt1n0gastricadenocarcinoma |